Company Description
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally.
It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives.
Its Personal Care segment provides a range of natural, nature-derived, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers.
The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding.
Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone.
It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical.
The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022.
Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1924 |
| Industry | Specialty Chemicals |
| Sector | Materials |
| Employees | 3,200 |
| CEO | Guillermo Novo |
Contact Details
Address: 8145 Blazer Drive Wilmington, Delaware 19808 United States | |
| Phone | 302 995 3000 |
| Website | ashland.com |
Stock Details
| Ticker Symbol | ASH |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001674862 |
| CUSIP Number | 044186104 |
| ISIN Number | US0441861046 |
| Employer ID | 81-2587835 |
| SIC Code | 5160 |
Key Executives
| Name | Position |
|---|---|
| Guillermo Novo | Chairman and Chief Executive Officer |
| John Kevin Willis | Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
| Karl R. Bostaph | Senior Vice President of Operations |
| Dr. Osama M. Musa Ph.D. | Senior Vice President and Chief Technology Officer |
| Alessandra Faccin Assis | Senior Vice President and GM of Life Sciences and Intermediates |
| William C. Whitaker C.F.A. | Director of Investor Relations |
| Robin E. Lampkin | Senior Vice President, General Counsel and Secretary |
| Eileen M. Drury | Senior Vice President and Chief Human Resources Officer |
| James P. Minicucci | Senior Vice President and GM of Personal Care |
| Dago Caceres | SVice President and General Manager of Specialty Additives |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 31, 2025 | SCHEDULE 13D/A | Filing |
| Jan 29, 2025 | 10-Q | Quarterly Report |
| Jan 28, 2025 | 8-K | Current Report |
| Jan 22, 2025 | 8-K | Current Report |
| Dec 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 9, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 9, 2024 | ARS | Filing |
| Dec 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 5, 2024 | 144 | Filing |
| Nov 25, 2024 | 8-K | Current Report |